US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ATYR PHARMA INC

0.7520

-0.0407-5.13%

Post-market: 0.78330.0313+4.16%19:29 EDT

Volume:1.30M

Turnover:986.04K

Market Cap:73.69M

PE:-0.94

High:0.7927

Open:0.7758

Low:0.7500

Close:0.7927

52wk High:7.29

52wk Low:0.6400

Shares:97.99M

Float Shares:95.97M

Volume Ratio:1.35

T/O Rate:1.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7971

EPS(LYR):-0.7971

ROE:-108.11%

ROA:-51.12%

PB:1.09

PE(LYR):-0.94

Loading ...

Overview Company News Filings

Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation

aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate

aTyr posts FY 2025 net loss of USD 74.1 million

aTyr Pharma Inc: Qtrly Shr Loss $0.14

THOMSON REUTERS

Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Awards Inducement Stock Options Under Nasdaq Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis

aTyr Pharma Inc - Type C Meeting Scheduled for Mid-April 2026

THOMSON REUTERS

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

THOMSON REUTERS

aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations

aTyr Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Stock Price

aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call

aTyr Pharma Faces Investor Class Action After Drug Trial Failure

aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call

aTyr Pharma Faces Investor Lawsuit After Drug Trial Failure

aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call

aTyr Pharma Faces Class Action After Stock Plummets on Failed Clinical Trial

aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud

aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATYR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.752,"timestamp":1774641600000,"preClose":0.7927,"halted":0,"volume":1299649,"hourTrading":{"tag":"盘后","latestPrice":0.7833,"preClose":0.752,"latestTime":"19:29 EDT","volume":9532,"amount":7207.4137,"timestamp":1774654159261,"change":0.0313,"changeRate":0.041622,"amplitude":0.041622},"delay":0,"changeRate":-0.05134350952441019,"floatShares":95966000,"shares":97986634,"eps":-0.797093,"marketStatus":"Market Closed","change":-0.0407,"latestTime":"03-27 16:00:00 EDT","open":0.7758,"high":0.7927,"low":0.75,"amount":986042.5266159,"amplitude":0.053867,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.797093,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.7927,"preHourTrading":{"tag":"盘前","latestPrice":0.7815,"preClose":0.7927,"latestTime":"09:04 EDT","volume":2275,"amount":1780.6882275,"timestamp":1774616645023,"change":-0.0112,"changeRate":-0.014129,"amplitude":0.016021},"postHourTrading":{"tag":"盘后","latestPrice":0.7833,"preClose":0.752,"latestTime":"19:29 EDT","volume":9532,"amount":7207.4137,"timestamp":1774654159261,"change":0.0313,"changeRate":0.041622,"amplitude":0.041622},"volumeRatio":1.352,"impliedVol":1.7754,"impliedVolPercentile":0.5498},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":95966000,"roa":"-51.12%","roe":"-108.11%","lyrEps":-0.797093,"volumeRatio":1.352,"shares":97986634,"dividePrice":0,"high":0.7927,"amplitude":0.053867,"preClose":0.7927,"low":0.75,"week52Low":0.64,"pbRate":"1.09","psRate":"387.82","week52High":7.2904,"institutionHeld":0,"latestPrice":0.752,"eps":-0.797093,"divideRate":0,"volume":1299649,"delay":0,"ttmEps":-0.797093,"open":0.7758,"prevYearClose":0.7831,"prevWeekClose":0.8083,"prevMonthClose":0.9598,"prevQuarterClose":0.7831,"fiveDayClose":0.8083,"twentyDayClose":0.9598,"sixtyDayClose":0.745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"ATYR","fiscalQuarterEnding":"2025/12","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-11-06","symbol":"ATYR","fiscalQuarterEnding":"2025/09","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-08-07","symbol":"ATYR","fiscalQuarterEnding":"2025/06","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-05-07","symbol":"ATYR","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.2,"hold":0.7,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7,"analysts":10,"updateTime":1762574400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2026-03-26","current":-0.943428,"percent":0.875,"low":-9.277729,"twenty":-5.204043,"median":-3.78886,"eighty":-1.217121,"high":-0.849664,"avg":-3.640171,"sd":2.288425,"marketCap":78372333},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-09","current":-4.680309,"twenty":-4.75642,"median":-4.108234,"eighty":-2.431359,"marketCap":296787764},{"date":"2025-05-16","current":-4.210769,"twenty":-4.743267,"median":-4.133647,"eighty":-2.432827,"marketCap":267013308},{"date":"2025-05-23","current":-5.333641,"twenty":-4.774836,"median":-4.143453,"eighty":-2.440266,"marketCap":338216856},{"date":"2025-05-30","current":-5.972275,"twenty":-4.816072,"median":-4.149872,"eighty":-2.448121,"marketCap":378713875},{"date":"2025-06-06","current":-7.509205,"twenty":-4.87282,"median":-4.17922,"eighty":-2.448121,"marketCap":476173732},{"date":"2025-06-13","current":-7.621493,"twenty":-4.919528,"median":-4.191509,"eighty":-2.448121,"marketCap":483294087},{"date":"2025-06-20","current":-7.256559,"twenty":-4.932682,"median":-4.241665,"eighty":-2.448121,"marketCap":460152934},{"date":"2025-06-27","current":-7.453062,"twenty":-4.985297,"median":-4.254757,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-03","current":-7.453062,"twenty":-5.016231,"median":-4.28094,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-11","current":-7.481134,"twenty":-5.080005,"median":-4.302543,"eighty":-2.458595,"marketCap":474393643},{"date":"2025-07-18","current":-8.126785,"twenty":-5.119466,"median":-4.327606,"eighty":-2.461213,"marketCap":515335684},{"date":"2025-07-25","current":-7.796941,"twenty":-5.18655,"median":-4.339852,"eighty":-2.468042,"marketCap":494419641},{"date":"2025-08-01","current":-6.624944,"twenty":-5.237851,"median":-4.345289,"eighty":-2.473394,"marketCap":420100937},{"date":"2025-08-08","current":-7.354811,"twenty":-5.277498,"median":-4.380221,"eighty":-2.474305,"marketCap":466383244},{"date":"2025-08-15","current":-7.337565,"twenty":-5.711388,"median":-4.396173,"eighty":-2.474305,"marketCap":488953303},{"date":"2025-08-22","current":-7.278747,"twenty":-6.338611,"median":-4.472298,"eighty":-2.474305,"marketCap":485033838},{"date":"2025-08-29","current":-7.866928,"twenty":-6.868599,"median":-4.491152,"eighty":-2.474305,"marketCap":524228491},{"date":"2025-09-05","current":-8.043383,"twenty":-7.051635,"median":-4.498606,"eighty":-2.474305,"marketCap":535986887},{"date":"2025-09-12","current":-7.734587,"twenty":-7.202339,"median":-4.538489,"eighty":-2.478232,"marketCap":515409694},{"date":"2025-09-19","current":-1.543977,"twenty":-7.202339,"median":-4.511608,"eighty":-2.474305,"marketCap":102885965},{"date":"2025-09-26","current":-1.313556,"twenty":-7.183573,"median":-4.496851,"eighty":-2.466335,"marketCap":87531460},{"date":"2025-10-03","current":-1.043875,"twenty":-7.138658,"median":-4.477635,"eighty":-2.448121,"marketCap":69560711},{"date":"2025-10-10","current":-1.401343,"twenty":-7.082514,"median":-4.406529,"eighty":-2.442885,"marketCap":93381262},{"date":"2025-10-17","current":-1.470454,"twenty":-7.051635,"median":-4.382946,"eighty":-2.421938,"marketCap":97986634},{"date":"2025-10-24","current":-1.430458,"twenty":-7.012335,"median":-4.346398,"eighty":-2.388848,"marketCap":95321397},{"date":"2025-10-31","current":-1.305763,"twenty":-6.956191,"median":-4.340306,"eighty":-2.375054,"marketCap":87012130},{"date":"2025-11-07","current":-1.004754,"twenty":-6.884883,"median":-4.327606,"eighty":-2.330297,"marketCap":75479104},{"date":"2025-11-14","current":-0.930535,"twenty":-6.741157,"median":-4.315074,"eighty":-2.317206,"marketCap":69903664},{"date":"2025-11-21","current":-0.849664,"twenty":-6.641787,"median":-4.294031,"eighty":-2.285786,"marketCap":63828493},{"date":"2025-11-28","current":-1.018058,"twenty":-6.613715,"median":-4.254757,"eighty":-2.277852,"marketCap":76478567},{"date":"2025-12-05","current":-1.079755,"twenty":-6.467742,"median":-4.247271,"eighty":-2.236667,"marketCap":81113335},{"date":"2025-12-12","current":-0.998232,"twenty":-6.153338,"median":-4.191509,"eighty":-2.08841,"marketCap":74989171},{"date":"2025-12-19","current":-0.9171,"twenty":-5.941396,"median":-4.17922,"eighty":-1.996274,"marketCap":68894402},{"date":"2025-12-26","current":-0.962753,"twenty":-5.88149,"median":-4.159816,"eighty":-1.970681,"marketCap":72323934},{"date":"2026-01-02","current":-1.02145,"twenty":-5.827142,"median":-4.144316,"eighty":-1.58809,"marketCap":76733333},{"date":"2026-01-09","current":-0.945796,"twenty":-5.68245,"median":-4.143453,"eighty":-1.529272,"marketCap":71050108},{"date":"2026-01-16","current":-0.921535,"twenty":-5.590373,"median":-4.115174,"eighty":-1.499863,"marketCap":69227556},{"date":"2026-01-23","current":-0.973579,"twenty":-5.463588,"median":-4.100824,"eighty":-1.470454,"marketCap":73137223},{"date":"2026-01-30","current":-1.109494,"twenty":-5.353291,"median":-4.058383,"eighty":-1.430928,"marketCap":83347430},{"date":"2026-02-06","current":-1.05745,"twenty":-5.277498,"median":-4.044799,"eighty":-1.420105,"marketCap":79437764},{"date":"2026-02-13","current":-1.16206,"twenty":-5.263462,"median":-4.025068,"eighty":-1.381433,"marketCap":87296292},{"date":"2026-02-20","current":-1.369585,"twenty":-5.259961,"median":-3.990774,"eighty":-1.302178,"marketCap":102885965},{"date":"2026-02-27","current":-1.291323,"twenty":-5.252075,"median":-3.985607,"eighty":-1.296092,"marketCap":97006767},{"date":"2026-03-06","current":-1.193659,"twenty":-5.240481,"median":-3.979834,"eighty":-1.286732,"marketCap":88471608},{"date":"2026-03-13","current":-1.147622,"twenty":-5.227328,"median":-3.937701,"eighty":-1.255818,"marketCap":85059426},{"date":"2026-03-20","current":-1.094838,"twenty":-5.211936,"median":-3.872289,"eighty":-1.237152,"marketCap":81147183},{"date":"2026-03-27","current":-1.048668,"twenty":-5.203474,"median":-3.781997,"eighty":-1.214301,"marketCap":77725195}],"updateTime":1774687199528},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617528566","title":"Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2617528566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617528566?lang=en_us&edition=fundamental","pubTime":"2026-03-07 14:00","pubTimestamp":1772863234,"startTime":"0","endTime":"0","summary":"Atyr Pharma Inc. (ATYR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Atyr Pharma Inc. faces a significant listing ri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atyr-pharma-faces-nasdaq-delisting-risk-after-minimum-bid-price-violation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atyr-pharma-faces-nasdaq-delisting-risk-after-minimum-bid-price-violation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NQmain","ATYR"],"gpt_icon":0},{"id":"2617754655","title":"aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617754655","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617754655?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:03","pubTimestamp":1772744613,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 13.04 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51082508/atyr-pharma-q4-eps-0-14-beats-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2617751215","title":"aTyr posts FY 2025 net loss of USD 74.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617751215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617751215?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:02","pubTimestamp":1772744535,"startTime":"0","endTime":"0","summary":"aTyr posts FY 2025 net loss of USD 74.1 million               aTyr Pharma reported a Q4 2025 net loss attributable to shareholders of USD 14.0 million, or USD 0.14 per share (basic and diluted), on no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLc9fMpk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4585","SG9999014013.SGD","LU2210150020.SGD","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2617579237","title":"aTyr Pharma Inc: Qtrly Shr Loss $0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579237?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA8PVVNF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2617575947","title":"Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575947?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744460,"startTime":"0","endTime":"0","summary":"Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis.\"In 2025 we announced results from our Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease  where a significant proportion of patients develop chronic or progressive disease with debilitating symptoms despite current treatment options. This marked an important milestone, not only for the broader sarcoidosis community, but also for aTyr, as it was the Company's largest and first Phase 3 study of a tRNA synthetase-derived therapy generated from our platform,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.\"We are ready and look forward to engaging with the U.S. Food and Drug Administration  in mid-April to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4604","03160","ATYR","BK4555","BK4139","BK4585","BK4099","TM"],"gpt_icon":0},{"id":"2613075292","title":"aTyr Pharma Awards Inducement Stock Options Under Nasdaq Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613075292?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621269,"startTime":"0","endTime":"0","summary":"aTyr Pharma said its board compensation committee granted two new employees nonstatutory stock options covering a total of 12,200 common shares at an exercise price of $0.98 per share. The options vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. The awards were made under the company’s 2022 Inducement Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL6Kw0J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","ATYR","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","NDAQ","BK4139","SG9999014013.SGD","LU2210150020.SGD","SG9999014039.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2613629205","title":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613629205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613629205?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nTUA6JTTJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2608487190","title":"BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608487190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608487190?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:25","pubTimestamp":1770125110,"startTime":"0","endTime":"0","summary":"BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary SarcoidosisFeb 3 (Reuters) - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES SCHEDULING OF FDA TYP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":1},{"id":"2608838879","title":"aTyr Pharma Inc - Type C Meeting Scheduled for Mid-April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608838879?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2608687600","title":"aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608687600?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2589643358","title":"aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2589643358","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589643358?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:42","pubTimestamp":1765197737,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims that the company made false and misleading statements and concealed material adverse information regarding the efficacy of its drug candidate, Efzofitimod, specifically its ability to allow patients to completely taper their steroid usage. The situation escalated when, on September 15, 2025, aTyr Pharma announced that its EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% drop in the company's stock price in a single day. The law firm Levi & Korsinsky is representing shareholders in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9zM605:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2589170838","title":"aTyr Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2589170838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589170838?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:06","pubTimestamp":1764968802,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. has received a deficiency notice from the Nasdaq Stock Market, indicating that its common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, as mandated by Nasdaq Listing Rule 5550. The company has 180 calendar days, until June 2, 2026, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for 10 consecutive business days. If aTyr Pharma does not meet this requirement, it may be eligible for an additional 180-day compliance period, provided it satisfies other listing standards. Failure to regain compliance could result in the company's stock being delisted from the Nasdaq Capital Market. The company is actively monitoring the situation and evaluating options to address the deficiency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8VQzMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2589889291","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2589889291","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589889291?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:42","pubTimestamp":1764938539,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL5b24Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2588046898","title":"aTyr Pharma Faces Investor Class Action After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046898","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046898?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:39","pubTimestamp":1764765553,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements and concealed material adverse information regarding the efficacy of its drug candidate, Efzofitimod, particularly its ability to enable patients to taper off steroid usage. The situation came to light on September 15, 2025, when the company announced that its EFZO-FIT study did not meet its primary endpoint. Following this announcement, the company's stock price dropped sharply from $6.03 to $1.02 per share, representing an 83.2% decline in a single day. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbdxwTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2588108058","title":"aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2588108058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588108058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:39","pubTimestamp":1764679156,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4LwsL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2586787834","title":"aTyr Pharma Faces Investor Lawsuit After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2586787834","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586787834?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:42","pubTimestamp":1764074533,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The complaint alleges that the company made overly positive statements and concealed adverse information about the efficacy of its drug Efzofitimod, particularly regarding its ability to allow patients to fully taper steroid use. The litigation follows an investor call on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to the stock price plummeting from $6.03 to $1.02 per share in a single day. The case is being handled by Levi & Korsinsky, a law firm specializing in securities litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6cHSxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2585148455","title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148455","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585148455?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:42","pubTimestamp":1763728942,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL99J8b1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2584867949","title":"aTyr Pharma Faces Class Action After Stock Plummets on Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584867949","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584867949?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:44","pubTimestamp":1763556257,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The lawsuit claims that the company issued positive statements about the efficacy of its drug, Efzofitimod, while concealing material adverse facts about its ability to allow patients to completely taper steroid usage. The truth was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a sharp decline in the company's stock price from $6.03 to $1.02 per share. The legal action seeks to recover damages for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLccFkFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2584556608","title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2584556608","media":"Reuters","labels":["shareholding","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584556608?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:30","pubTimestamp":1763422215,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The legal action claims that the company misled shareholders, resulting in financial losses. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in complex securities litigation and recovering significant sums for affected shareholders. Investors who experienced losses during the specified period are encouraged to seek more information about their potential eligibility in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL99x9N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","news_tag":"shareholding,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2584625803","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625803","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625803?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384430,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL2jGdxg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}